Good news amid the Covid fight to complete the therapy offer currently available. The Pfizer laboratory announced they have started clinical trials in two of their locations – on in the United States, the other in Belgium – for a potential coronavirus medicine created as a pill. Called “PF 07321332”, this therapy has been given to 60 volunteers aged 18 to 60 as part of this clinical trial.
As for this medicine, it involves a “protease inhibitor”, which is a molecule inhibiting an enzyme cutting peptide bonds of the proteins, preventing the virus from doing what it is programmed for. A genuine “custom antiviral” developed to directly aim at the “spine” of the virus and prevent it from developing in the nasal cavities, the mouth, and the lungs.
“We have designed PF-07321332 as a potential oral therapy that could be prescribed at the first sign of infection, without requiring that patients are hospitalized or in critical care", said Mikael Dolsten, chief scientific officer and president, worldwide research, development and medical of Pfizer in a release.
A clinical trial expected to take place for 145 days, in three steps. The first one is to assess the tolerance of the treatment “as the dose is increased” and “if there are significant side effects”. The second step aims at the same goals, but with “multiple doses”. The last phase of the clinical trial is to test the medicine as a tablet, but also in a liquid form.
A clinical trial that – if conclusive – is to test the medicine in people infected by Covid for 28 days, in a testing phase. As for marketing, if everything goes as expected, it could happen by the end of the year.